Physician profile
Joye Dado
NPI 1750339420
$5,628.41
in general payments reported to CMS, 2019-2025
11 companies · $1,341 in 2025
The $1,341 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $893 · 2022: $1,032 · 2023: $1,157 · 2024: $1,206 · 2025: $1,341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,704.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,703.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $2,374.04 | 2021-2025 | Dovato, Cabenuva, Apretude |
| Gilead Sciences, INC. | $1,513.94 | 2022-2025 | Yeztugo, Biktarvy |
| Abbvie INC. | $1,032.38 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $341.92 | 2021-2025 | Pifeltro, Delstrigo, Isentress |
| Axsome Therapeutics, INC. | $247.99 | 2024-2025 | Auvelity |
| Theratechnologies INC. | $25.13 | 2024 | Egrifta Sv |
| Lilly USA, LLC | $23.96 | 2023 | Mounjaro |
| Antares Pharma, INC. | $22.09 | 2022 | |
| Hologic Sales and Service, LLC | $17.24 | 2021 | |
| Novo Nordisk INC | $15.53 | 2022 | |
| Phathom Pharmaceuticals, INC. | $14.19 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joye Dado listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.